Stoke Therapeutics (STOK) Accumulated Depreciation (2018 - 2025)

Stoke Therapeutics has reported Accumulated Depreciation for 8 years, with the latest figure at $10.1 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation rose 14.67% year-over-year to $10.1 million; the trailing twelve-month figure through Dec 2025 stood at $10.1 million (up 14.67% YoY), and the FY2025 full-year result was $10.1 million, up 14.67% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $10.1 million, up from $8.8 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $10.1 million in Q4 2025, with the low at $2.7 million in Q4 2021.
• Average Accumulated Depreciation over 5 years is $6.5 million, with a median of $6.7 million recorded in 2023.
• Year-over-year, Accumulated Depreciation surged 58.57% in 2023 and grew 14.67% in 2025.
• Tracing STOK's Accumulated Depreciation over 5 years: stood at $2.7 million in 2021, then jumped by 58.1% to $4.2 million in 2022, then surged by 58.57% to $6.7 million in 2023, then soared by 32.63% to $8.8 million in 2024, then gained by 14.67% to $10.1 million in 2025.
• The last three Accumulated Depreciation figures came in at $10.1 million (Q4 2025), $8.8 million (Q4 2024), and $6.7 million (Q4 2023), per Business Quant data.

Peer Comparison